New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Lexaria Bioscience Corp. (LEXX) vs TScan Therapeutics, Inc. (TCRX)
- Lexaria Bioscience Corp. LEXX 4.03 −10.24%
- TScan Therapeutics, Inc. TCRX 0.15 +7.14%
Lexaria Bioscience Corp. and TScan Therapeutics, Inc. are both Biotechnology companies. Lexaria Bioscience Corp. and TScan Therapeutics, Inc. are of similar size ($9.5M and $9.4M). Lexaria Bioscience Corp. grew revenue faster over the last twelve months: 52.0% against −38.4%. Lexaria Bioscience Corp. has the higher net margin (−1,686.1% vs −2,219.2%) and the lower return on invested capital (−662.6% vs 0.00%). Across the 18 metrics below, Lexaria Bioscience Corp. leads on 9 and TScan Therapeutics, Inc. on 9.
Valuation
Profitability
| Metric | LEXX | TCRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.62% | 100.00% | 70.18% |
| Operating margin | (1,683.06%) | (2,246.84%) | 0.00% |
| Net margin | (1,686.05%) | (2,219.19%) | 0.00% |
| Free cash flow margin | (1,494.56%) | (2,152.72%) | 0.00% |
| Return on equity | (162.60%) | (126.45%) | (51.58%) |
| Return on assets | (134.20%) | (57.03%) | (45.91%) |
| Return on invested capital | (662.56%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack